The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 13, 2021
Filed:
Jan. 31, 2019
Applicant:
Biocon Limited, Bangalore, IN;
Inventors:
Nagaraj Govindappa, Karnataka, IN;
Sreesha P. Srinivasa, Bangalore, IN;
Usha Bughani, Bangalore, IN;
Reshmi Nair, Bengaluru, IN;
Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 14/705 (2006.01); C07K 14/495 (2006.01); C07K 14/71 (2006.01); C07K 14/00 (2006.01); A61K 39/395 (2006.01); A61K 38/17 (2006.01); C12N 15/62 (2006.01); G01N 33/68 (2006.01); C07K 16/32 (2006.01); C07K 14/65 (2006.01); C07K 7/08 (2006.01); A61K 48/00 (2006.01); C07K 16/30 (2006.01); A61K 38/10 (2006.01); A61K 45/06 (2006.01); C12N 5/00 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/62 (2013.01); A61K 38/10 (2013.01); A61K 38/179 (2013.01); A61K 39/395 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 48/005 (2013.01); C07K 7/08 (2013.01); C07K 14/00 (2013.01); C07K 14/495 (2013.01); C07K 14/65 (2013.01); C07K 14/70532 (2013.01); C07K 14/70596 (2013.01); C07K 14/71 (2013.01); C07K 16/2818 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/2878 (2013.01); C07K 16/2887 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C12N 5/0018 (2013.01); G01N 33/6854 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2121/00 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/732 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/33 (2013.01); C12N 2500/22 (2013.01);
Abstract
The present invention provides for a composition and a method for treating a subject afflicted with a cancer, wherein the composition comprises therapeutically effective amounts of: (a) an anti-Programmed Death-Ligand 1 (PD-L1) antibody and (b) a targeted/immunomodulatory fusion protein comprising at least one tumor targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.